Boutique Diagnostics

Digital Health Market Access Consulting Firm

Digital Health Solutions

Access

Expanding CENTIVIS offering to Nordics, Benelux and Point of Care diagnostics

Expanding CENTIVIS offering to Nordics, Benelux and Point of Care diagnostics

We are pleased to partner up with Synergus RWE, Wimenco and Expand Healthcare Consulting to further expand our diagnostics market access and health policy consulting offer.

3+1 Policy Initiatives That Will Influence Diagnostics (IVD) Access

3+1 Policy Initiatives That Will Influence Diagnostics (IVD) Access

The diagnostics industry is facing increasing policy attention. Policymakers push for broader access, better affordability and safer than ever solutions. Institutions, like the European Union (EU) and World Health Organization (WHO), are involved in introducing new regulations.

Find out what are the latest policy initiatives and how will they impact access for IVD solutions.

Five Diagnostics (IVD) Access Challenges & Potential Actions

Five Diagnostics (IVD) Access Challenges & Potential Actions

Five Diagnostics (IVD) Access Challenges & Potential Actions:

  1. Diagnostics are complex solutions

  2. Less clinical investment

  3. Cost-based reimbursement

  4. Lack of clear funding processes and guidelines

  5. Limited-use cases in digital diagnostics reimbursement

5 Payer trends in Diagnostics

5 Payer trends in Diagnostics

In Vitro Diagnostics is going through exciting times. Pricing, reimbursement, policy topics are getting more and more relevant in the industry.

We have summarized 5 recent Payer trends, shaping the industry.

Do you want to have the collection of the supporting trend examples, please drop us a line.

Do you see other relevant trends that we might have missed, please comment.

WHO Essential Diagnostics List (EDL) – 3 likely impacts to the diagnostics industry

WHO Essential Diagnostics List (EDL) – 3 likely impacts to the diagnostics industry

WHO Essential Diagnostics List (EDL) – 3 likely impacts to the diagnostics industry

The diagnostics industry is facing increasing policy attention. The In Vitro Diagnostic Device Regulation (IVDR) will newly regulate the European approval system, the new EU Health Technology Assessment (HTA) proposal is already on the table and World Health Organization (WHO) has just released the first Essential Diagnostics List (EDL).

Similar concept, Essential Medicines List (EML) has been around for 40 years. Looking at the history of EML what can the diagnostics industry expect?

CENTIVIS awarded ‘Approved Facilitator’ status for NICE META Tool

CENTIVIS awarded ‘Approved Facilitator’ status for NICE META Tool

CENTIVIS awarded ‘Approved Facilitator’ status for latest NICE META Tool

CENTIVIS has recently been approved by NICE (National Institute for Health and Care Excellence) as one of the limited number of qualified Medtech Early Technical Assessment (META) Tool facilitators.

NICE has developed the META tool to help medical technology developers understand what evidence is needed to make a convincing case to payers and commissioners.

"With NICE META tool our diagnostics and digital health clients will benefit from a structured, streamlined and affordable evidence review to better capture the value of their diagnostic and digital health solutions"

Do you want to know more? SCHEDULE A CALL or visit the product page

Norbert